AT2

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Research, Extracellular matrix, B cell, ECM, Regeneration, Idiopathic pulmonary fibrosis, AT2, Inflammation, Lung, SWAP, Respiratory Research, Macrophage, IPF, Pulmonary fibrosis, Fibrosis, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-0.... The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.

Key Points: 
  • The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.
  • Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by areas of myofibroblast accumulation and extracellular matrix (ECM) deposition, disruption of alveolar architecture, and restricted lung physiology.
  • In pulmonary fibrosis, multiple cell types may need to be targeted to provide a regenerative environment facilitating repair.
  • “This work published in Respiratory Research represents a breakthrough in understanding the role of the Wnt pathway in lung fibrosis and the potential for Wnt mimetics to reduce fibrosis and improve lung function.”

Pulmonary Fibrosis Foundation Expands Research Into Devastating Lung Disease

Retrieved on: 
Tuesday, November 1, 2022
JAMA, MD, Air pollution, Interstitial lung disease, University of Chicago, Idiopathic disease, Particulates, Better Business Bureau, Research, Patient, PFF, Pulmonary fibrosis, Mortality, University of Pittsburgh, University of California, View, University of Pennsylvania, PF, Telehealth, University, Quality of life, Foundation, BBB, National Health Council, Workplace exposure monitoring, Survival, ATS, Impact, MS, Journal, Multimedia, Typesetting, Charity Navigator, AT2, Workplace, Association, American Medical Association, Caregiver, Cell Reports, Degenerative disease, National, Medical device

Dr. Gillian Goobie(PFF Scholar Class of 2020), University of Pittsburgh, studies the role that air pollution plays in the development and progression of interstitial lung diseases.

Key Points: 
  • Dr. Gillian Goobie(PFF Scholar Class of 2020), University of Pittsburgh, studies the role that air pollution plays in the development and progression of interstitial lung diseases.
  • Her paper, Association of Particulate Matter Exposure With Lung Function and Mortality Among Patients With Fibrotic Interstitial Lung Disease , was published in the Journal of the American Medical Association Internal Medicine on Oct. 17, 2022.
  • Dr. Jeremy Katzen(PFF Scholar Class of 2019), University of Pennsylvania, received a National Institutes of Health K08 award.
  • Dr. Katzen's research focuses on understanding the impairment process ofalveolar type-2 (AT2) cells, which are important cellular components of normal lung function and repair, and how that may contribute to the initiation and progression of lung fibrosis
    The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis.

CoreSite Expands into Atlanta and Orlando Data Center Markets

Retrieved on: 
Tuesday, June 7, 2022
Data Management, Technology, Other Technology, Software, Internet, Hardware, Cloud, Leadership, American Tower, SVP, Marietta Street, OCX, Ecosystem, Growth, AT2, Technology, Acquisition, NYSE, CoreSite, Open Cloud Computing Interface, Heart, CSPS, AT1, Satellite navigation device, Atlanta

CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (American Tower), today announced its expansion into the Atlanta and Orlando markets with the integration of three American Tower assets into CoreSites data center ecosystem: Atlanta AT1 (55 Marietta Street NW, Atlanta, GA, 30303), Atlanta AT2 (1130 Powers Ferry Place, Marietta, GA, 30067) and Orlando OR1 (9701 S. John Young Parkway, Orlando, FL, 32819).

Key Points: 
  • CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (American Tower), today announced its expansion into the Atlanta and Orlando markets with the integration of three American Tower assets into CoreSites data center ecosystem: Atlanta AT1 (55 Marietta Street NW, Atlanta, GA, 30303), Atlanta AT2 (1130 Powers Ferry Place, Marietta, GA, 30067) and Orlando OR1 (9701 S. John Young Parkway, Orlando, FL, 32819).
  • As one of the fastest-growing data center markets, Atlanta has the third-largest concentration of Fortune 500 companies in the United States.
  • CoreSites Atlanta data center campus includes AT1, which is located in the second most interconnected building in the heart of downtown Atlanta, and AT2 in Marietta.
  • The integration of these assets into the CoreSite data center portfolio expands upon CoreSites offering to now include 27 data centers in 10 markets, 450+ networks, 23 native cloud onramps and 35,000+ interconnections.

Curebase selected to launch a clinical investigation of a digital therapeutic for IPF

Retrieved on: 
Thursday, April 21, 2022
Patient, Breathe Me, CEO, Idiopathic pulmonary fibrosis, AT2, Clinical trial, Research, SAMD, Anxiety, Grammatical mood, DTA, Degenerative disease, DCT, CBT, Artificial intelligence, Lviv, SAN, LinkedIn, Life expectancy, Trial of the century, Heart, Nasdaq Stockholm, Digital therapeutics, C21, Angiotensin, Solution, Depression, Cognitive behavioral therapy, Intelligence, Digital, IPF, Physician, Partnership, Disease, Health, Single-frequency network, Cros, Therapy, Fatigue, Pharmaceutical industry, Medical device, Vicor Corporation

SAN FRANCISCO, April 21, 2022 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, today announced the initiation of the pilot phase of COMPANION, the first clinical investigation of a new digital therapeutic (DTx) for patients with IPF, a rare lung disease. The DTx is owned by Vicore Pharma, a clinical-stage pharmaceutical company.

Key Points: 
  • Curebase has extensive experience in the DTx space and is the premier thought leader for the Digital Therapeutics Alliance (DTA) in building resources to effectively execute DTx clinical research.
  • Their decentralized clinical trial model ensures more diverse and far-reaching studies because unique populations which typically are underrepresented in clinical trials can be included.
  • "This decentralized clinical investigation also gives us an opportunity to rethink the traditional clinical trial model while keeping the patient in focus."
  • VP04 develops a clinically validated digital therapeutic (DTx) a digital cognitive behavioral therapy specifically developed to treat anxiety and depression in adults with IPF.

Hankook Tire to Provide Two Original Equipment Fitments for 2022 Nissan Frontier

Retrieved on: 
Monday, November 1, 2021
OE, Technology, HT, Snow, Pathfinder, Rogue, Hankook Tire, AT2, Forbes, All-terrain vehicle, Noise, Marketing, CarPlay, Investment, 4WD, SUV, Calibuso v. Bank of America Corp., Environment, Multimedia, Nissan Frontier, Traction, Frontier, Forbes Global 2000, Nissan Sentra, Tire manufacturing, Heavy equipment

"As the 2022 Nissan Frontier seeks to provide drivers with versatile on-and-off road performance, the Hankook Dynapro HT and Dynapro AT2 are the perfect fitments for the job," said Jeongho Park, senior vice president, Hankook OE Division.

Key Points: 
  • "As the 2022 Nissan Frontier seeks to provide drivers with versatile on-and-off road performance, the Hankook Dynapro HT and Dynapro AT2 are the perfect fitments for the job," said Jeongho Park, senior vice president, Hankook OE Division.
  • "We are pleased to provide Nissan with two fitments for the redesigned 2022 Nissan Frontier," said Moonwha Hong, vice president of OE development, Hankook Tire.
  • Hankook Tire has been an original equipment supplier for Nissan since 2013 and has provided fitments for popular models such as the Altima, Pathfinder, Sentra and Rogue.
  • Hankook Tire America is a subsidiary of Hankook Tire Co., Ltd., a Forbes Global 2000 company headquartered in Seoul, Korea.

Sorento Plug-in Hybrids Primed and Prepped for Rebelle Rally

Retrieved on: 
Friday, October 8, 2021
Shades of green, Multimedia, Marketing, Safety, Girls, Inc., Telluride, KMC, Sport utility vehicle, Movement, Hankook Tire, Woman, AT2, Sand, Color, K5, LGE, CEO, Photography, Sorento, NBA, Team Spirit, Toy

With Hankook as the tire sponsor, the Sorento rally vehicles sport Hankook decals along with the Girls Inc. logo on the rear passenger windows.

Key Points: 
  • With Hankook as the tire sponsor, the Sorento rally vehicles sport Hankook decals along with the Girls Inc. logo on the rear passenger windows.
  • "The Rebelle Rally is an inspiration to women everywhere," said Russell Wager, vice president of marketing, Kia America.
  • Should one of the Kia teams win the award, Girls Inc. will receive an additional $5,000 from Rebelle Rally.
  • The Rebelle Rally takes place on Oct. 7-16 and you can follow Kia's teams on RebelleRally.com.

Hankook Tire Unveils New Rugged Terrain Dynapro XT and Next Generation Dynapro AT2 Xtreme

Retrieved on: 
Wednesday, October 6, 2021
All-terrain vehicle, Forbes Global 2000, Light truck, Forbes, Snow, Multimedia, SUV, MT2, AT2, Marketing, Environment, Puncture, Technology, XT, CUV, Traction, Hankook Tire, Investment, Calibuso v. Bank of America Corp., Noise, Rail transport, Road, Tire manufacturing

NASHVILLE, Tenn., Oct. 6, 2021 /PRNewswire/ --Leading global tire maker Hankook Tire today announced an expansion of its Dynapro line of products to include the brand-new Rugged Terrain Dynapro XT and next generation Dynapro AT2 Xtreme.

Key Points: 
  • NASHVILLE, Tenn., Oct. 6, 2021 /PRNewswire/ --Leading global tire maker Hankook Tire today announced an expansion of its Dynapro line of products to include the brand-new Rugged Terrain Dynapro XT and next generation Dynapro AT2 Xtreme.
  • The Dynapro XT is available now in 30 sizes, while the Dynapro AT2 Xtreme is currently available in 32 sizes.
  • With the addition of the Dynapro XT and Dynapro AT2 Xtreme, Hankook's Dynapro family of products now covers on-road, off-road, all-terrain and rugged terrain segments to suit the needs of both Light Truck and SUV/CUV consumers.
  • The Dynapro XT and Dynapro AT2 Xtreme are available now, with the continued release of additional sizes throughout the remainder of 2021 and 2022.